GlassScriptPhysician profile
Gurbakhash Kaur
NPI 1548609571
$91,947.98
in general payments reported to CMS, 2019-2025
21 companies · $40K in 2025
The $40K reported for 2025 was more than what 94% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2021: $214 · 2022: $8,102 · 2023: $27K · 2024: $16K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $66K · Food and Beverage: $5,498 · Honoraria: $4,306 · Travel and Lodging: $4,205 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,520.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $65,792.00 |
| Food and Beverage | $5,498.02 |
| Honoraria | $4,305.63 |
| Travel and Lodging | $4,205.36 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,520.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $29,259.77 | 2023-2025 | Yescarta, Tecartus |
| Genzyme Corporation | $14,190.96 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $13,200.50 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $12,407.56 | 2021-2025 | Tecvayli, Darzalex, Carvykti |
| Pfizer INC. | $6,756.07 | 2023-2025 | |
| Bio Products Laboratory USA, INC. | $4,630.47 | 2023 | Gammaplex, Coagadex |
| Janssen Global Services, LLC | $3,307.78 | 2025 | |
| Celgene Corporation | $3,022.59 | 2019-2024 | |
| Janssen Biotech, INC. | $2,258.48 | 2022-2025 | Darzalex, Tecvayli, Carvykti |
| Astrazeneca Pharmaceuticals LP | $1,754.69 | 2023-2025 | Wainua, Calquence |
| Karyopharm Therapeutics INC. | $323.88 | 2025 | Xpovio |
| Amgen INC. | $156.25 | 2019 | |
| Menarini Silicon Biosystems, INC. | $145.74 | 2024 | |
| Beigene USA, INC. | $125.00 | 2022 | |
| Astellas Pharma US INC | $99.99 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $88.55 | 2024 | |
| Astrazeneca Uk Limited | $52.20 | 2024 | Calquence |
| Abbvie INC. | $51.92 | 2019-2023 | |
| Janssen Research & Development, LLC | $50.07 | 2022 | |
| Genentech USA, INC. | $40.01 | 2022-2023 | |
| Legend Biotech USA INC. | $25.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurbakhash Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.